StockNews.AI
QTRX
StockNews.AI
22 days

Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC

1. QTRX launches two novel phospho-tau assays for Alzheimer's detection. 2. The launch strengthens their position in the blood-based biomarker market.

2m saved
Insight
Article

FAQ

Why Bullish?

The introduction of new assays could lead to increased revenue and market share, reminiscent of past product launches that boosted stock prices significantly.

How important is it?

The introduction of first-to-market assays enhances QTRX's competitive edge, likely attracting investor attention.

Why Long Term?

Successful adoption of these assays will drive sustained growth, similar to how prior innovations led to enhanced customer interest over time.

Related Companies

ADUSALNYABT
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The announcement comes alongside Quanterix's robust presence at the Alzheimer's Association International Conference (.

Related News